Case Report

Severe Stomatitis Complicating Treatment With Pegylated-Interferon α-2a and Ribavirin in an HCV-Infected Patient

Authors: Joaquín Borrás-Blasco, PharmD, PhD, J Primo MD, PhD, J Dolores Rosique-Robles, PharmD, PhD, MD, Elvira Casterá, PharmD, F Javier Abad PharmD, PhD, I Jiménez, MD

Abstract


Objective: To report a case of severe stomatitis probably induced by peginterferon α-2a.


Methods and Results: A 42-year-old man with chronic hepatitis C genotype 1b commenced treatment with peginterferon α-2a 180 μg subcutaneously weekly and ribavirin 1000 mg/d orally. Twenty-eight days after commencing treatment, the patient experienced difficulties with swallowing, dryness of the mouth, stomatitis, and pain. Diagnosis of stomatitis was made. He did not complain of any other adverse effect of peginterferon α-2a and ribavirin. Both medications were discontinued. The withdrawal of peginterferon α-2a was followed by the resolution of the oral lesions in three weeks. The patient was followed up in the outpatient clinic at one month and at three months, and he was asymptomatic.


Conclusions: Manufacturers of peginterferon α-2a suggest that mouth ulceration, stomatitis, dysphagia, and glossitis are considered adverse reactions of this medication. In this case, the most likely cause of the stomatitis was considered to be peginterferon α-2a because of the close temporal relationship between exposure to the drug and onset of symptoms, as well as the rapid resolution of the symptoms and signs after peginterferon α-2a was discontinued. An objective causality assessment revealed that a adverse drug event was possible. Clinicians should be aware of this potentially adverse effect of a widely used drug.



This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002;24:1363–1383.
 
2. Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother 2006;40:74–82.
 
3. Pearlman BL. Hepatitis C infection: a clinical review. South Med J 2004;97:364–373.
 
4. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444–2451.
 
5. Abdollahi M, Radfar M. A review of drug-induced oral reactions. J Contemp Dent Pract 2003;4:10–31.
 
6. Malnick SD, Beergabel M, Lurie Y. Treatment of chronic hepatitis C virus infection. Ann Pharmacother 2000;34:1156–1164.
 
7. Farah R, Farah R, Makhoul N. Interferon-induced pulmonary sarcoidosis. Int J Clin Pharmacol Ther 2005;43:441–443.
 
8. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–1672.
 
9. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395–403.
 
10. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237–S244.
 
11. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711–1719.
 
12. Qaseem T, Jafri W, Abid S, et al. A case report of painful oral ulcerations associated with the use of alpha interferon in a patient with chronic hepatitis due to non-A non-B non-C virus. Mil Med 1993;158:126–127.
 
13. Dalekos GN, Christodoulou D, Kistis KG, et al. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998;10:933–939.
 
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.